Future needs--diagnostic services.

M. Nicolas-Chanoine

DOI: https://doi.org/10.1046/J.1469-0691.2000.00127.X

IF: 13.31

2000-08-01

Clinical Microbiology and Infection

Abstract:

What problem does this paper attempt to address?

Vitiligo: Focus on Clinical Aspects, Immunopathogenesis, and Therapy

Katia Boniface,Julien Seneschal,Mauro Picardo,Alain Taïeb

DOI: https://doi.org/10.1007/s12016-017-8622-7

2017-07-06

Abstract:Vitiligo is an acquired chronic depigmenting disorder of the skin, with an estimated prevalence of 0.5% of the general population, characterized by the development of white macules resulting from a loss of epidermal melanocytes. The nomenclature has been revised after an extensive international work within the vitiligo global issues consensus conference, and vitiligo (formerly non-segmental vitiligo) is now a consensus umbrella term for all forms of generalized vitiligo. Two other subsets of vitiligo are segmental vitiligo and unclassified/undetermined vitiligo, which corresponds to focal disease and rare variants. A series of hypopigmented disorders may masquerade as vitiligo, and some of them need to be ruled out by specific procedures including a skin biopsy. Multiple mechanisms are involved in melanocyte disappearance, namely genetic predisposition, environmental triggers, metabolic abnormalities, impaired renewal, and altered inflammatory and immune responses. The auto-immune/inflammatory theory is the leading hypothesis because (1) vitiligo is often associated with autoimmune diseases; (2) most vitiligo susceptibility loci identified through genome-wide association studies encode immunomodulatory proteins; and (3) prominent immune cell infiltrates are found in the perilesional margin of actively depigmenting skin. However, other studies support melanocyte intrinsic abnormalities with poor adaptation of melanocytes to stressors leading to melanocyte instability in the basal layer, and release of danger signals important for the activation of the immune system. Recent progress in the understanding of immune pathomechanisms opens interesting perspectives for innovative treatment strategies. The proof of concept in humans of targeting of the IFNγ /Th1 pathway is much awaited. The interplay between oxidative stress and altered immune responses suggests that additional strategies aiming at limiting type I interferon activation pathway as background stabilizing therapies could be an interesting approach in vitiligo. This review covers classification and clinical aspects, pathophysiology with emphasis on immunopathogenesis, and promising therapeutic approaches.

immunology,allergy
Vitiligo: Mechanisms of Pathogenesis and Treatment

Michael L Frisoli,Kingsley Essien,John E Harris,Michael L. Frisoli,John E. Harris

DOI: https://doi.org/10.1146/annurev-immunol-100919-023531

IF: 29.7

2020-04-26

Annual Review of Immunology

Abstract:Vitiligo is an autoimmune disease of the skin that targets pigment-producing melanocytes and results in patches of depigmentation that are visible as white spots. Recent research studies have yielded a strong mechanistic understanding of this disease. Autoreactive cytotoxic CD8 + T cells engage melanocytes and promote disease progression through the local production of IFN-γ, and IFN-γ-induced chemokines are then secreted from surrounding keratinocytes to further recruit T cells to the skin through a positive-feedback loop. Both topical and systemic treatments that block IFN-γ signaling can effectively reverse vitiligo in humans; however, disease relapse is common after stopping treatments. Autoreactive resident memory T cells are responsible for relapse, and new treatment strategies focus on eliminating these cells to promote long-lasting benefit. Here, we discuss basic, translational, and clinical research studies that provide insight into the pathogenesis of vitiligo, and how this insight has been utilized to create new targeted treatment strategies.

immunology
Vitiligo: Translational research and effective therapeutic strategies

Vishal Thakur,Anuradha Bishnoi,Keshavamurthy Vinay,Sendhil M. Kumaran,Davinder Parsad

DOI: https://doi.org/10.1111/pcmr.12974

2021-04-05

Abstract:This is an exciting phase of vitiligo research with the current understanding of vitiligo pathogenesis and its translation to successful treatment. The pathogenetic origin of vitiligo revolves around autoimmunity with supporting role from many other factors like oxidative stress, inherent melanocyte defects or defective keratinocytes and fibroblasts.Vitiligo can be classified into segmental or non‐segmental depending upon the clinical presentation or it can be classified as progressing or stable based on the activity of the disease.Vitiligo treatments need to be stratified depending upon which type of vitiligo we are treating and at which phase the vitiligo patient presents to us.There are two different aims of treatment of vitiligo. The first involves rescuing the melanocytes from the damage to arrest the depigmentation. The second strategy focuses on replenishing the melanocytes so that successful repigmentation is achieved. It is also important to maintain the disease in a stable phase or prevent relapse. As stability in non‐segmental vitiligo is a dynamic process, maintenance of the stability of repigmentation is also an important consideration in the management of vitiligo. In this review, we shall briefly discuss the current options and future insight into the management of vitiligo

dermatology,oncology,cell biology
Vitiligo: A focus on pathogenesis and its therapeutic implications

Christina Bergqvist,Khaled Ezzedine

DOI: https://doi.org/10.1111/1346-8138.15743

IF: 3.468

2021-01-06

The Journal of Dermatology

Abstract:Vitiligo is the most common depigmenting disorder affecting 0.1%–2% of the population worldwide. The characteristic white patches result from the selective loss of melanocytes. Sustained recent efforts have resulted in a detailed understanding of the genetic architecture of vitiligo. About 80% of vitiligo risk is attributable to genetic factors; and the rest (20%) is attributable to the environment. Over the past decade, substantial progress has been made in our understanding of the pathogenesis of vitiligo which is now clearly classified as an autoimmune disease. Melanocytes from patients with vitiligo are more susceptible to oxidative stress which begets the release of exosomes and inflammatory cytokines that will lead to activation of the innate immune response and subsequently to adaptive immune response through activation of autoreactive cytotoxic CD8+ T cells. These produce interferon‐γ (IFN‐γ) which promotes disease progression through IFN‐γ‐induced chemokine secretion from surrounding keratinocytes to further recruit T cells to the skin through a positive feedback loop. CD8 tissue‐resident memory T cells are in turn responsible for long‐term maintenance and potential relapse of vitiligo in human patients through cytokine‐mediated recruitment of T cells from the circulation. This review summarizes the current knowledge on vitiligo and attempt to give an overview of the future in vitiligo treatment.
Vitiligo: advances in pathophysiology research and treatment development

Zhussipbek Mukhatayev,I. Caroline Le Poole

DOI: https://doi.org/10.1016/j.molmed.2024.04.009

2024-05-06

Trends in Molecular Medicine

Abstract:The autoimmune condition vitiligo, characterized by skin depigmentation, presents challenges for effective treatment design, with Janus kinase (JAK) inhibitors and other repurposed drugs offering a promising strategy for symptom management. This review explores advantages and shortcomings of current therapies, while presenting the urgent need for further innovative approaches. We emphasize the growing understanding of autoimmune involvement in vitiligo, highlighting several novel treatment avenues including relieving melanocyte stress, preventing dendritic cell activation, halting T cell migration, and suppressing inflammation and autoimmunity. Integrating psychodrama therapy to remediate stress alongside medical interventions marks a holistic approach to enhance patient well-being. The molecular underpinnings of vitiligo care are covered, emphasizing exciting advances revolutionizing vitiligo treatment and improving the quality of life for affected individuals.

biochemistry & molecular biology,cell biology,medicine, research & experimental
Clinical Features, Immunopathogenesis, and Therapeutic Strategies in Vitiligo

Yinghan Wang,Shuli Li,Chunying Li

DOI: https://doi.org/10.1007/s12016-021-08868-z

2021-07-20

Abstract:Vitiligo is an autoimmune disease of the skin characterized by epidermal melanocyte loss resulting in white patches, with an approximate prevalence of 0.5–2% worldwide. Several precipitating factors by chemical exposure and skin injury present commonly in patients with vitiligo. Although the diagnosis appears to be straightforward for the distinct clinical phenotype and specific histological features, vitiligo provides many challenges including chronicity, treatment resistance, frequent relapse, associated profound psychosocial effect, and negative impact on quality of life. Multiple mechanisms are involved in melanocyte disappearance, including genetics, environmental factors, and immune-mediated inflammation. Compelling evidence supports the melanocyte intrinsic abnormalities with poor adaptation to stressors leading to instability and release of danger signals, which will activate dendritic cells, natural killer cells, and innate lymphoid cells to initiate innate immunity, ultimately resulting in T-cell mediated adaptive immune response and melanocyte destruction. Importantly, the cross- talk between keratinocytes, melanocytes, and immune cells, such as interferon (IFN)-γ signaling pathway, builds inflammatory loops that give rise to the disease deterioration. Improved understanding of the immune pathogenesis of vitiligo has led to the development of new therapeutic options including Janus kinase (JAK) inhibitors targeting IFN-γ signaling pathways, which can effectively reverse depigmentation. Furthermore, definition of treatment goals and integration of comorbid diseases into vitiligo management have revolutionized the way vitiligo is treated. In this review, we highlight recent developments in vitiligo clinical aspects and immune pathogenesis. Our key objective is to raise awareness of the complexity of this disease, the potential of prospective therapy strategies, and the need for early and comprehensive management.

immunology,allergy
Vitiligo: An Autoimmune Skin Disease and its Immunomodulatory Therapeutic Intervention

Wei-Ling Chang,Woan-Ruoh Lee,Yung-Che Kuo,Yen-Hua Huang

DOI: https://doi.org/10.3389/fcell.2021.797026

IF: 5.5

2021-12-14

Frontiers in Cell and Developmental Biology

Abstract:Vitiligo is a chronic autoimmune depigmenting skin disorder characterized by patches of the skin losing functional melanocytes. Multiple combinatorial factors are involved in disease development, among which immune T cells play a prominent role. The immune cells implicated in melanocyte destruction through adaptive immunity include CD8 + cytotoxic T cells and regulatory T cells, and aberrantly activated skin-resident memory T cells also play a role in melanocyte destruction. Over the past several years, major progress in understanding vitiligo pathogenesis has led to the development of targeted therapies. Janus kinase (JAK) inhibitors, which share the similar mechanism that autoactivates CD8 + T cells in chronic inflammatory diseases, have been reported to have therapeutic significance in vitiligo. Recently, immunomodulatory therapeutic interventions in vitiligo have been emerging. Mesenchymal stem cells (MSCs) regulate cytokine secretion and the balance of T-cell subsets, which makes them a promising cell-based treatment option for autoimmune diseases. The induction of MSC-mediated immunomodulation is complicated and occurs by contact-dependent mechanisms and soluble extracellular vesicle (EV) mediators. EVs released from MSCs contain various growth factors and cytokines with anti-inflammatory effects in the skin immune response. Here, we summarize and discuss the progress to date in targeted therapies that immunomodulate the niche environment of vitiligo, from the clinical trial of JAK inhibitors to the potential of MSCs and MSC-EVs. The available information was collected to highlight the need for further research into the treatment of vitiligo.

cell biology,developmental biology
[Therapy of patients of cerebral motor disorders].

G. Tardieu

1958-06-01

Abstract:
A view of dataflow*

K. Gostelow,Robert E. Thomas

DOI: https://doi.org/10.1109/MARK.1979.8817119

1979-06-01

Abstract:In 1946 John von Neumann outlined an organization for computers 1 that has dominated the languages and architecture of machines to this day—the familiar sequential, one-word-at-a-time instruction stream which modifies the contents of a memory. Although the von Neumann model has proved to be a viable and powerful approach to computation, we have chosen to explore other models of computation to determine if they offer advantages in ease of programming, exploitation of concurrency and performance. A primary motivation is new technology such as large scale integration (LSI) which has greatly expanded the range of choice in computer design.
Management of the refractory vitiligo patient: current therapeutic strategies and future options

Xinju Wang,Wei Wu,Jianru Chen,Chunying Li,Shuli Li

DOI: https://doi.org/10.3389/fimmu.2023.1294919

IF: 7.3

2024-01-05

Frontiers in Immunology

Abstract:Vitiligo is an autoimmune disease that leads to disfiguring depigmented lesions of skin and mucosa. Although effective treatments are available for vitiligo, there are still some patients with poor responses to conventional treatment. Refractory vitiligo lesions are mostly located on exposed sites such as acral sites and lips, leading to significant life stress. Understanding the causes of refractory vitiligo and developing targeted treatments are essential to enhance vitiligo outcomes. In this review, we summarized recent treatment approaches and some potential methods for refractory vitiligo. Janus kinase inhibitors have shown efficacy in refractory vitiligo. A variety of surgical interventions and fractional carbon dioxide laser have been widely applied to combination therapies. Furthermore, melanocyte regeneration and activation therapies are potentially effective strategies. Patients with refractory vitiligo should be referred to psychological monitoring and interventions to reduce the potential pathogenic effects of chronic stress. Finally, methods for depigmentation and camouflage may be beneficial in achieving uniform skin color and improved quality of life. Our ultimate focus is to provide alternative options for refractory vitiligo and to bring inspiration to future research.

immunology
The enigma and challenges of vitiligo pathophysiology and treatment

Zalfa A. Abdel‐Malek,Christian Jordan,Tina Ho,Parth Rajendrakumar Upadhyay,Alan Fleischer,Iltefat Hamzavi

DOI: https://doi.org/10.1111/pcmr.12878

2020-04-12

Abstract:Vitiligo is the most common acquired pigmentary disorder, which afflicts 0.5‐1% of the world population, and is characterized by depigmented skin patches resulting from melanocyte loss. Vitiligo has a complex etiology, and varies in its manifestations, progression, and response to treatment. It presents as an autoimmune disease, evidenced by circulating melanocyte‐specific antibodies, and association with other autoimmune diseases. However, autoimmunity may be secondary to the high oxidative stress in vitiligo skin and to intrinsic defects in melanocytes and their microenvironment, which contribute to aberrant stress response, neo‐antigenicity, and susceptibility of melanocytes to immune attack and apoptosis. There is also a genetic predisposition to vitiligo, which sensitizes melanocytes to environmental agents, such as phenolic compounds. Currently, there are different treatment modalities for re‐pigmenting vitiligo skin. However, when repigmentation is achieved, the major challenge is maintaining the pigmentation, which is lost in 40% of cases. In this review, we present an overview of the clinical aspects of vitiligo, its pathophysiology, the intrinsic defects in melanocytes and their microenvironment, and treatment strategies. Based on lessons from the biology of human melanocytes, we present our perspective of how repigmentation of vitiligo skin can be achieved and sustained.

dermatology,oncology,cell biology
An update on Vitiligo pathogenesis

Julien Seneschal,Katia Boniface,Andrea D’Arino,Mauro Picardo

DOI: https://doi.org/10.1111/pcmr.12949

2020-12-15

Abstract:Vitiligo, the most common depigmenting disorder of the skin, is undergoing a period of intense advances both in disease understanding and therapeutic possibilities leading the way to the beginning of a new era for the disorder. Its pathophysiology has gathered the attention of researchers for years and many advances have been made in the clarification of the interaction between different factors that result in depigmented macule formation. The complex interplay between non‐immunological and immunological factors in vitiligo is key for the development of the disease and the participation of cells other than melanocytes, such as keratinocytes, fibroblasts, natural killer cells and innate lymphoid cells has been shown. Recent advances have also brought to the understanding of the complex part played by a specific subtype of T‐cells: T‐resident memory cells. This review analyses some of the most recent insights in vitiligo pathogenesis underlining the interactions between different cell types, which are the basis for the therapeutic approaches under development.

dermatology,oncology,cell biology
Emerging drugs for the treatment of vitiligo

Priyanka Karagaiah,Yan Valle,Julia Sigova,Nicola Zerbinati,Petar Vojvodic,Davinder Parsad,Robert A. Schwartz,Stephan Grabbe,Mohamad Goldust,Torello Lotti

DOI: https://doi.org/10.1080/14728214.2020.1712358

2020-01-02

Expert Opinion on Emerging Drugs

Abstract:Introduction: Vitiligo is a relatively common autoimmune depigmenting disorder of the skin. There has been a great advance in understanding the pathological basis, which has led to the development and utilization of various new molecules in treating vitiligo. This review aims at a comprehensively describing the treatments available and the emerging treatment aspects and the scope for future developments.Areas covered: This study comprehensively summarizes the current concepts in the pathogenesis of vitiligo with special focus on the cytokine and signaling pathways, which are the targets for newer drugs. JAK kinase signaling pathways and the cytokines involved are the focus of vitiligo treatment in current research, followed by antioxidant mechanisms and repigmenting mechanisms. Topical immunosuppressants may be an alternative to steroids in localized vitiligo. Newer repigmenting agents like basic fibroblast growth factors, afamelanotide have been included and a special emphasis is laid on the upcoming targeted immunotherapy.Expert opinion: The treatment of vitiligo needs to be multimodal with emphasis on targeting different limbs of the pathogenesis. Topical and oral JAK inhibitors are the most promising new class of drugs currently available for treating vitiligo and acts best in conjunction with NB-UVB.

pharmacology & pharmacy
Understanding mechanisms of autoimmunity through translational research in vitiligo

James P Strassner,John E Harris

DOI: https://doi.org/10.1016/j.coi.2016.09.008

IF: 7.268

2016-12-01

Current Opinion in Immunology

Abstract:Vitiligo is an autoimmune disease of the skin that leads to life-altering depigmentation and remains difficult to treat. However, clinical observations and translational studies over 30-40 years have led to the development of an insightful working model of disease pathogenesis: Genetic risk spanning both immune and melanocyte functions is pushed over a threshold by known and suspected environmental factors to initiate autoimmune T cell-mediated killing of melanocytes. While under cellular stress, melanocytes appear to signal innate immunity to activate T cells. Once the autoimmune T cell response is established, the IFN-γ-STAT1-CXCL10 signaling axis becomes the primary inflammatory pathway driving both progression and maintenance of vitiligo. This pathway is a tempting target for both existing and developing pharmaceuticals, but further detailing how melanocytes signal their own demise may also lead to new therapeutic targets. Research in vitiligo may be the future key to understand the pathogenesis of organ-specific autoimmunity, as vitiligo is common, reversible, progresses over the life of the individual, has been relatively well-defined, and is quite easy to study using translational and clinical approaches. What is revealed in these studies can lead to innovative treatments and also help elucidate the principles that underlie similar organ-specific autoimmune diseases, especially in cases where the target organ is less accessible.

immunology
José M. Seco, Emilio Quiñoá, and Ricardo Riguera: The assignment of the absolute configuration by NMR using chiral derivatizing agents: a practical guide

T. Wenzel

DOI: https://doi.org/10.1007/s00216-015-9062-y

2015-10-05

Analytical and Bioanalytical Chemistry

Abstract:
Understanding Vitiligo: Causes, Diagnosis, Promising Advances in Treatment and Management and the Impact on Mental Health

Tadikonda Rama Rao,Hafsa Sharmeen,Afshaan Tabassum,Sena Jessy Jasmine

DOI: https://doi.org/10.22270/jddt.v14i4.6503

2024-04-15

Journal of Drug Delivery and Therapeutics

Abstract:Vitiligo is a chronic skin disorder characterized by the loss of pigmentation, resulting in white patches on the skin. The condition arises from the destruction of melanocytes, the cells responsible for producing melanin, the pigment that gives colour to the skin, hair, and eyes. Although the exact etiology of vitiligo remains elusive, it is believed to involve a complex interplay of genetic, autoimmune, and environmental factors. This overview provides the key aspects of vitiligo, including its epidemiology, pathogenesis, clinical manifestations, and current treatment approaches. The prevalence of vitiligo varies globally, affecting individuals of all ethnic backgrounds and age groups. The autoimmune hypothesis proposes that the immune system mistakenly targets and attacks melanocytes, leading to their destruction. Triggering factors, such as oxidative stress, viral infections, and neural factors, may contribute to the initiation and progression of vitiligo. Clinically, vitiligo can significantly impact the quality of life for affected individuals, both psychologically and socially. The distribution and extent of involvement vary, and the condition can affect any part of the body. Various treatment modalities are available for vitiligo, ranging from topical corticosteroids and calcineurin inhibitors to phototherapy and surgical interventions. While these approaches may help to re-pigment the skin to some extent, there is no definitive cure, and the outcomes can be unpredictable. Ongoing research is focused on understanding the molecular mechanisms underlying vitiligo and developing targeted therapies to address the root causes of the disease. Keywords: Vitiligo, Autoimmune, Melanocytes, Pigmentation, Corticosteroids, Quality of life.
Translational Research in Vitiligo

Erica L Katz,John E Harris,Erica L. Katz,John E. Harris

DOI: https://doi.org/10.3389/fimmu.2021.624517

IF: 7.3

2021-03-02

Frontiers in Immunology

Abstract:Vitiligo is a disease of the skin characterized by the appearance of white spots. Significant progress has been made in understanding vitiligo pathogenesis over the past 30 years, but only through perseverance, collaboration, and open-minded discussion. Early hypotheses considered roles for innervation, microvascular anomalies, oxidative stress, defects in melanocyte adhesion, autoimmunity, somatic mosaicism, and genetics. Because theories about pathogenesis drive experimental design, focus, and even therapeutic approach, it is important to consider their impact on our current understanding about vitiligo. Animal models allow researchers to perform mechanistic studies, and the development of improved patient sample collection methods provides a platform for translational studies in vitiligo that can also be applied to understand other autoimmune diseases that are more difficult to study in human samples. Here we discuss the history of vitiligo translational research, recent advances, and their implications for new treatment approaches.

immunology
Current Concepts of Vitiligo Immunopathogenesis

Nika Hlača,Tina Žagar,Marija Kaštelan,Ines Brajac,Larisa Prpić-Massari

DOI: https://doi.org/10.3390/biomedicines10071639

IF: 4.757

2022-07-08

Biomedicines

Abstract:Vitiligo is an acquired immune-mediated disorder of pigmentation clinically characterized by well-defined depigmented or chalk-white macules and patches on the skin. The prevalence of vitiligo varies by geographical area, affecting 0.5% to 2% of the population. The disease imposes a significant psychological burden due to its major impact on patients' social and emotional aspects of life. Given its autoimmune background, vitiligo is frequently associated with other autoimmune diseases or immune-mediated diseases. Vitiligo is a multifaceted disorder that involves both genetic predisposition and environmental triggers. In recent years, major predisposing genetic loci for the development of vitiligo have been discovered. The current findings emphasize the critical role of immune cells and their mediators in the immunopathogenesis of vitiligo. Oxidative-stress-mediated activation of innate immunity cells such as dendritic cells, natural killer, and ILC-1 cells is thought to be a key event in the early onset of vitiligo. Innate immunity cells serve as a bridge to adaptive immunity cells including T helper 1 cells, cytotoxic T cells and resident memory T cells. IFN-γ is the primary cytokine mediator that activates the JAK/STAT pathway, causing keratinocytes to produce the key chemokines CXCL9 and CXCL10. Complex interactions between immune and non-immune cells finally result in apoptosis of melanocytes. This paper summarizes current knowledge on the etiological and genetic factors that contribute to vitiligo, with a focus on immunopathogenesis and the key cellular and cytokine players in the disease's inflammatory pathways.
Advances in vitiligo: Update on therapeutic targets

Yifei Feng,Yan Lu

DOI: https://doi.org/10.3389/fimmu.2022.986918

IF: 7.3

2022-08-31

Frontiers in Immunology

Abstract:Vitiligo, whose treatment remains a serious concern and challenge, is an autoimmune skin disease characterized by patches of depigmentation. The increasing application of molecular-targeted therapy in skin diseases, such as psoriasis and systemic lupus erythematosus, has dramatically improved their condition. Besides, there is a favorable effect of repigmentation in the treatment of the above diseases combined with vitiligo, implying that molecular-targeted therapy may also have utility in vitiligo treatment. Recently, the role of cytokine and signaling pathways in vitiligo pathogenesis are increasingly recognized. Thus, investigations are underway targeting the molecules described above. In this paper, we present a synopsis of current practices in vitiligo treatment and introduce the improvement in identifying new molecular targets and applying molecular-targeted therapies, including those under development in vitiligo treatment, providing valuable insight into establishing further precision medicine for vitiligo patients.

immunology
Independent effects of phytohemagglutinin on cell fusion and attachment by newcastle disease virus.

P. Polos,W. R. Gallaher

DOI: https://doi.org/10.1016/0042-6822(82)90087-3

IF: 3.513

1982-06-01

Virology

Abstract:

Future needs--diagnostic services.

Vitiligo: Focus on Clinical Aspects, Immunopathogenesis, and Therapy

Vitiligo: Mechanisms of Pathogenesis and Treatment

Vitiligo: Translational research and effective therapeutic strategies

Vitiligo: A focus on pathogenesis and its therapeutic implications

Vitiligo: advances in pathophysiology research and treatment development

Clinical Features, Immunopathogenesis, and Therapeutic Strategies in Vitiligo

Vitiligo: An Autoimmune Skin Disease and its Immunomodulatory Therapeutic Intervention

[Therapy of patients of cerebral motor disorders].

A view of dataflow*

Management of the refractory vitiligo patient: current therapeutic strategies and future options

The enigma and challenges of vitiligo pathophysiology and treatment

An update on Vitiligo pathogenesis

Emerging drugs for the treatment of vitiligo

Understanding mechanisms of autoimmunity through translational research in vitiligo

José M. Seco, Emilio Quiñoá, and Ricardo Riguera: The assignment of the absolute configuration by NMR using chiral derivatizing agents: a practical guide

Understanding Vitiligo: Causes, Diagnosis, Promising Advances in Treatment and Management and the Impact on Mental Health

Translational Research in Vitiligo

Current Concepts of Vitiligo Immunopathogenesis

Advances in vitiligo: Update on therapeutic targets

Independent effects of phytohemagglutinin on cell fusion and attachment by newcastle disease virus.